Integrated drug resistance action framework for HIV, hepatitis B and C and sexually transmitted infections, 2026–2030

The WHO Integrated Drug Resistance Action Framework for HIV, Hepatitis B and C, and Sexually Transmitted Infections (2026–2030) sets out a unified global strategy to combat rising drug resistance, which threatens decades of progress against these major infectious diseases. Developed through broad consultation and aligned with WHO strategies and the Sustainable Development Goals, it promotes a people-centred and equitable public health approach across five domains: prevention and response, surveillance, research and innovation, laboratory capacity, and governance. The framework stresses country ownership, sustainability, and strong partnerships among governments, communities, researchers, and global stakeholders. By combining disease-specific and cross-cutting measures, it aims to strengthen health systems, ensure access to high-quality and stigma-free services, and preserve the effectiveness of essential medicines. Its ultimate goal is to prevent the emergence and spread of drug resistance so that ending AIDS and the epidemics of hepatitis B, hepatitis C, and STIs by 2030 remains within reach.